1-8 of 8
Michael R. McDevitt
Close
Sort by
Journal Articles

Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33; HuM195) in Acute Myeloid Leukemia (AML)

Joseph G. Jurcic, MD, Todd L. Rosenblat, MD, Michael R. McDevitt, PhD, Neeta Pandit-Taskar, MD, Jorge A. Carrasquillo, MD, Suzanne M. Chanel, RN, Kevin Zikaras, BS, Mark G. Frattini, MD, PhD, Peter G. Maslak, M.D., Dragan Cicic, MD, Steven M. Larson, MD, David A. Scheinberg, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 768.
https://doi.org/10.1182/blood.V118.21.768.768
Published: 2011
Journal Articles

Multivalent DNA Aptamer-Based Therapeutic Agents for Lymphoma and Leukemia.

Prabodhika Mallikaratchy, PhD, Alessandro Ruggiero, MD, William Maguire, Kelly Piersanti, Jeffrey Gardner, Carlos Villa, Freddy Escorcia, Maria Lia Palomba, MD, Mark Heaney, MD, PhD, Michael R. McDevitt, PhD, David A. Scheinberg, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 2711.
https://doi.org/10.1182/blood.V114.22.2711.2711
Published: 2009
Journal Articles

Vascular Endothelial-Cadherin Targeted Alpha-Particle Mediated Vascular Killing and Remodeling Augments Subsequent Chemotherapeutic Efficacy.

Freddy E Escorcia, Erik Henke, PhD, Michael R. McDevitt, PhD, Carlos Villa, Peter Smith-Jones, PhD, Ronald Blasberg, MD, Robert Benezra, David A. Scheinberg, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 3054.
https://doi.org/10.1182/blood.V114.22.3054.3054
Published: 2009
Journal Articles

Sequential Cytarabine and Alpha-Particle Immunotherapy with Bismuth-213 ( 213 Bi)-Labeled-HuM195 (Lintuzumab) for Acute Myeloid Leukemia (AML)

Todd Rosenblat, MD, MS, Michael R. McDevitt, PhD, Deborah A. Mulford, MD, Neeta Pandit-Taskar, MD, Mark A. Weiss, MD, Mark L. Heaney, MD, PhD, Suzanne Chanel, RN, Alfred Morgenstern, PhD, Steven M. Larson, MD, David A. Scheinberg, MD, PhD, Joseph G. Jurcic, MD
Journal: Blood
Blood (2008) 112 (11): 2983.
https://doi.org/10.1182/blood.V112.11.2983.2983
Published: 2008
Journal Articles

Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 ( 225 Ac)-HuM195 (Anti-CD33) in Acute Myeloid Leukemia (AML).

Todd L. Rosenblat, MD, Michael R. McDevitt, PhD, Neeta Pandit-Taskar, MD, Jorge A. Carrasquillo, MD, Suzanne Chanel, RN, Mark G. Frattini, MD, PhD, Steven M. Larson, MD, David A. Scheinberg, MD, PhD, Joseph G. Jurcic, MD
Journal: Blood
Blood (2007) 110 (11): 910.
https://doi.org/10.1182/blood.V110.11.910.910
Published: 2007
Journal Articles

Sequential Therapy with Cytarabine and Bismuth-213 ( 213 Bi)-Labeled-HuM195 (Anti-CD33) for Acute Myeloid Leukemia (AML).

Deborah A. Mulford, M.D., Neeta Pandit-Taskar, M.D., Michael R. McDevitt, Ph.D., Ronald D. Finn, Ph.D., Mark A. Weiss, M.D., Christos Apostolidis, Ph.D., Alfred Morgenstern, Ph.D., Chaitanya R. Divgi, M.D., Steven M. Larson, Ph.D., David A. Scheinberg, M.D., Ph.D., Joseph G. Jurcic, M.D.
Journal: Blood
Blood (2004) 104 (11): 1790.
https://doi.org/10.1182/blood.V104.11.1790.1790
Published: 2004
Journal Articles

Targeted deletion of T-cell clones using alpha-emitting suicide MHC tetramers

Rui Rong Yuan, Phillip Wong, Michael R. McDevitt, Ekaterina Doubrovina, Ingrid Leiner, William Bornmann, Richard O'Reilly, Eric G. Pamer, David A. Scheinberg
Journal: Blood
Blood (2004) 104 (8): 2397–2402.
https://doi.org/10.1182/blood-2004-01-0324
Published: 2004
Journal Articles

Targeted α particle immunotherapy for myeloid leukemia

Clinical Trials & Observations
Joseph G. Jurcic, Steven M. Larson, George Sgouros, Michael R. McDevitt, Ronald D. Finn, Chaitanya R. Divgi, Åse M. Ballangrud, Klaus A. Hamacher, Dangshe Ma, John L. Humm, Martin W. Brechbiel, Roger Molinet, David A. Scheinberg
Journal: Blood
Blood (2002) 100 (4): 1233–1239.
https://doi.org/10.1182/blood.V100.4.1233.h81602001233_1233_1239
Published: 2002